ArticleFrontiers in cardiovascular medicine2026
Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Statins are the cornerstone of secondary prevention in atherosclerotic cardiovascular disease (ASCVD), but their association with new-onset diabetes mellitus (NODM) remains incompletely defined. Whether the risk of NODM differs among individual statins within the same intensity class has not been well established. Methods: Using the Korean National Health Insurance Service (NHIS) database, we identified 29,826 patients with established ASCVD who initiated statin therapy between 2009 and 2012 and were followed for up to five years. The primary endpoint was incident NODM, defined by new diagnostic coding plus antidiabetic medication use after a three-year window period. The secondary endpoint was major adverse cardiac and cerebrovascular events (MACCE). Results: Overall, 11,918 patients (40.0%) developed NODM. The incidence of NODM was comparable between high- and moderate-intensity statins (42.9% vs. 41.1%). In the moderate-intensity group, rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin, while fluvastatin and pitavastatin showed no significant differences. MACCE incidence was similar across statins. Discussion: In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.